Andrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
|
|
- Ashley Hensley
- 5 years ago
- Views:
Transcription
1 What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. Please have this discussion with your own doctor, that s how you ll get care that s most appropriate for you. Dr. Young here at this major medical meeting, ASH, American Society of Hematology, what do you feel is an important finding related to aplastic anemia? So I think that the most important new finding in aplastic anemia over the course of the last year has really been this growing relationship between telomeres and their relationship with bone marrow failure, aplastic anemia and other diseases. And presented at this year's ASH as well as published over the course of last year is the prognostic importance of short, shorter telomeres of white cell and the outcome in patients with aplastic anemia. Telomeres are the ends of the chromosomes. They get shorter naturally as we age, and we know that there is a subset of aplastic anemia that is inherited that's due to genetic defects in telomere repair. We also realize that patients even who have normal telomeres but are shorter, in the shorter range, those patients don't do as well as patients who have telomeres that are longer, normal, still in the normal range but longer than this very short group. And that has an enormous prognostic significance and also potentially will help patients choose therapy and even develop new therapies. Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG? Yes. So there have been a number of studies actually mainly of horse ATG alone or rabbit ATG alone. And some of the smaller studies when rabbit ATG was introduced into the American market for other purposes, not for aplastic anemia, some of the smaller studies suggested that rabbit ATG might be better than horse ATG for the treatment of patients. And there are some reasons to think that rabbit might be superior because it's a more potent immunosuppressant. It works better for example in the setting of renal transplant, both preventing rejection and treating rejection. And it also has some interesting properties in the test tube, for example stimulating cells that we think are good cells in immune disease like T regulatory cells. So we at NIH in our hospital where we do see patients with aplastic anemia wished to compare these two treatments. We actually had a three-arm study to begin with actually a third drug as well, which we were not able to continue. So we performed a full study to look at whether rabbit or horse were better as inducing hematologic responses. That's 1
2 the important factor in how well patients do, whether they can respond to immunosuppressant therapy, and we were very surprised at the result. Actually, it was completely opposite of that which we hypothesized. Rabbit was significantly inferior to horse, almost half of the response rate to rabbit compared to horse. We actually had powered the studies statistically to show that sort of difference but expected rabbit to do better than horse. So horse won the race. So that's standard therapy in the United States, horse ATG, and will remain standard therapy. As you alluded, unfortunately, horse ATG, which is produced actually in Michigan by Pfizer's horses that are immunized up there, horse ATG is not available in other parts of the world, and so that is a major problem for Europe and for Asia. Now, an abstract that was presented as a poster here at ASH this year suggested that maybe in Asia that doesn't make a difference, and there may be ethnic differences, and patients seem historically to do as well with rabbit now as they did with horse in the past. But there are other studies from South America and from Europe here at ASH that although they weren't randomized trials like the one that was performed at Bethesda they've looked again at how patients are doing with rabbit now compared to how patients did with horse before, and they're actually even worse than our results that patients are really doing much more poorly with rabbit in Europe and in South America than they are--than they did with horse. So there are efforts at the moment, some of them successful, to bring horse ATG back, to import it back into Europe, and that's been achieved in Italy and a couple of other countries. I think those efforts are continuing. Obviously having a paper published that's a randomized trial is going to be helpful, but there is going to have to be a shift in terms of how patients are treated based on this randomized trial. Tell us about newer immunosuppressant drugs. Well, Campath really hasn't been tested adequately in patients at the outset of their disease, so I don't think we actually have to go beyond Campath at the moment. We have to figure out whether Campath actually may work as first treatment because that would avoid what's often problematic for patients, with is cyclosporine, and it probably could be given to patients as an outpatient. Some small studies in Europe suggested that Campath was effective. We certainly think it's effective in patients who have relapsed or have refractory disease. When we did our big triple-arm study we didn't see Campath work very well, which is why we dropped it, but I think Campath deserves another look, maybe in older patients, patients who can wait a few months to see whether they respond and where treatment is not urgent. So I think Campath actually remains as a potential immunosuppressive agent. The horse-versus-rabbit study, laboratory data that were associated with that study suggested that T regulatory cells, which are a very popular subject of laboratory study in mice and in humans and a lot of different diseases from cancer to autoimmune diseases, the T regulatory cells were actually very low in the patients who were treated with rabbit, 2
3 whereas they returned to normal levels in the horse ATG-treated patients. And there are some specific cytokines that may induce T regulatory cells. So that's one direction that we will probably go at the NIH, starting with patients who either have relapsed or have refractory disease. So giving for example low doses of some of these cytokines again potentially in the outpatient setting, may be helpful to now more specifically modulate the immune response. I'll mention just one other agent that we reported here at ASH that isn't working on the immune system but is exciting because it's actually working on the bone marrow directly, and that's a drug called eltrombopag. That's actually a drug that's marketed now in the United States, approved by the FDA for the treatment of patients with idiopathic thrombocytopenic purpura. This is a very low platelet count due to immune causes. And we did a study in some of our most refractory patients, a couple of dozen of those patients, who had not responded to any immunosuppression and a lot of other therapies, and we were actually quite amazed that almost half of these patients showed significant improvements in their blood counts and also amazed that it was not restricted to platelets. So there it appears that this drug actually can affect the hematopoietic stem cell. And in some of these patients as we showed in one of the oral sessions, in some of these patients the bone marrows that were obtained at six months were actually normal in their cellularity, which is quite different from what we see in immunosuppression. So we're quite excited about actually having an agent that may work directly on the stem cell in addition to having drugs that can reduce the immune attack on the stem cells. And the hope is if the company is willing that we'll actually now start a new trial with standard immunosuppression and with the addition of this very well tolerated oral agent and be able to work on both sides of the immune system and on the bone marrow. We got a question from Gail in New Rochelle, New York. She wants to know is there any better understanding now of the cause of aplastic anemia. Unfortunately not. I think that the causes that most patients think about are environmental, that there's a drug that they have taken or a chemical that they might have been exposed to that caused their aplastic anemia, and I think there's actually been very little new information that would allow patients to go back and say, I know for sure that this is what led to my disease. Really, in most patients we see it's very hard to identify any environmental exposure with a singular exception, which is hepatitis, and some proportion of patients, probably between five and as many as 20 percent of patients who have aplastic anemia had a preceding hepatitis, usually a month or two before the onset of their aplastic anemia. And I think once we understand what that hepatitis is about we'll know a lot about aplastic anemia, but it's not the normal sort of hepatitis due to hepatitis A virus or hepatitis B or hepatitis C virus. There's no known viral agent. We're looking for that as are other groups. But that's really the most distinct preceding trigger for whatever happens to the 3
4 immune system. Otherwise, in most patients there's no distinct history, and this often occurs in young people who are not taking any medical drugs or have any unusual exposures. And in that respect I think it's quite similar to many other immune-mediated diseases. Multiple sclerosis, inflammatory bowel disease, these also tend to occur in older children, young adults, and we don't think that those are caused by a specific chemical. There is something that does lead to an imbalance of the immune system and to a targeted attack on an organ, but really knowing exactly what that is has been elusive. Dr. Young, we got this question from Alise in Brooklyn, wants to know if there's a difference in response rates for people who have relapsed receiving Campath versus ATG. Actually, we've just published a paper. It's online in Blood now, which is a randomized study looking at the effectiveness of rabbit ATG and Campath in our patients at NIH, and they're about equivalent. So in our hands between 30 and 40 percent of patients who are refractory to horse ATG will respond to a second round of immunosuppression with rabbit or with Campath. And Campath we think may be easier to give because it doesn't require cyclosporine and again probably can be given in the outpatient department. In patients who have relapsed we've observed that many, more than half of patients who have relapsed will respond so Campath. So these drugs look to be about similar in their ability to rescue hematopoiesis, rescue bone marrow function in aplastic anemia patients. Dr. Young, you've been at this a long time. When you look at aplastic anemia are you encouraged with how we're doing now? Oh, I'm tremendously encouraged, but I have a long perspective, which is not often the perspective of somebody who has this disease and is ill and wants to get cured and be sick any more, especially young people who were fine a month or two earlier. When I first started to see aplastic anemia patients, which is a long time ago, back in the 1980s, the mortality rates were astronomical. Virtually everybody died, and they died very early on in the course of their disease. That's actually very rare now. It's really remarkable that--i think it's one of the great success stories in modern hematology that we've been able to take a disease that was uniformly fatal in my professional lifetime and convert it to one in which most patients can expect to do well with many different modalities, immunosuppression, bone marrow transplant, which has now been expanded for unrelated donors, other therapies, like the growth factors that I mentioned, so there would be--the survival rates, the response rates are actually most patients are going to do well. That's not everyone, but most patients are going to do well. And in addition we have stunning new laboratory data that come from the genetics of the immune system but especially of the hematopoietic system that will I think allow us to 4
5 really understand in individual patients much better what's driving the bone marrow failure and obviously be able to treat it. Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. Please have this discussion with your own doctor, that s how you ll get care that s most appropriate for you. 5
Dr. Gopal, are you encouraged in the direction of where research is headed and its benefit for patients?
Targeting the Tumor in Lymphoma July 8, 2009 Ajay Gopal Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient
More informationFine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013
Fine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013 John Corman, M.D. Medical Director, Floyd & Delores Jones Cancer Institute at Virginia Mason Virginia Mason Medical Center
More informationThe Latest in Non-Hodgkin Lymphoma News From ASCO
Patient Power Knowledge. Confidence. Hope. The Latest in Non-Hodgkin Lymphoma News From ASCO John Leonard, MD Associate Dean for Clinical Research Weill Cornell Medical College Please remember the opinions
More informationEpisode 93: What Role Stem Cells in Leukaemia?
Published on Up Close (https://upclose.unimelb.edu.au) Episode 93: What Role Stem Cells in Leukaemia? What Role Stem Cells in Leukaemia? VOICEOVER Welcome to Up Close, the research, opinion and analysis
More informationAdvances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson. Introduction
Advances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationOne of the areas where it's certainly made it difference is with the transplantation of the liver. Dr. Roberts thinks so much for joining us.
Benefits and Risks of Living Donor Liver Transplant Webcast May 28, 2008 John Roberts, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationTracking Genetic-Based Treatment Options for Inflammatory Bowel Disease
Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease Recorded on: June 25, 2013 Melvin Heyman, M.D. Chief of Pediatric Gastroenterology UCSF Medical Center Please remember the opinions
More informationBenefits of Survivorship Treatment Care Plans Webcast May 13, 2009 Scott Baker, M.D., M.S. Donald Wilhelm. Introduction
Benefits of Survivorship Treatment Care Plans Webcast May 13, 2009 Scott Baker, M.D., M.S. Donald Wilhelm Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationASCO 2016: Ask the Lung Cancer Experts
Live @ ASCO 2016: Ask the Lung Cancer Experts Charu Aggarwal, MD, MPH Assistant Professor of Medicine University of Pennsylvania Health System Liza Villaruz, MD Hematology/Oncology Specialist University
More informationPROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO
PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO 1 00:00:00,067 --> 00:00:10,968 2 00:00:10,968 --> 00:00:12,701 So, you were given a decision aid sheet 3 00:00:12,701 --> 00:00:14,567 about prostate
More informationWEEK 1: Feedback from Helen and Melissa - Friday 17 March 2017
Food As Medicine WEEK 1: Feedback from Helen and Melissa - Friday 17 March 2017 https://youtu.be/irvpha-bmwy HELEN TRUBY: Hi, everyone. Welcome to "Food as Medicine," week one Feedback. I'm Helen Truby
More informationDr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014
Patient Power Knowledge. Confidence. Hope. Dr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014 Michael Keating, MB, BS Professor of Medicine, Department of Leukemia
More informationHello and welcome to Patient Power sponsored by Northwestern Memorial Hospital. I'm Andrew Schorr.
Brain Tumor Clinical Trials Webcast November 22, 2011 Sean Grimm, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial Hospital, its medical
More informationClinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer
Clinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer Questions Answered by Andrea Apolo, MD is a Lasker Clinical Research Scholar and tenure-track
More informationBreast Cancer Imaging Webcast October 21, 2009 Peter Eby, M.D. Introduction
Breast Cancer Imaging Webcast October 21, 2009 Peter Eby, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or
More informationAiming for a CLL Treatment Home Run Recorded on June 1, 2014
Patient Power Knowledge. Confidence. Hope. Aiming for a CLL Treatment Home Run Recorded on June 1, 2014 Thomas Kipps, MD, PhD Deputy Director of Research Operations UC San Diego Moores Cancer Center Please
More informationCarrier Screening in your Practice Is it Time to Expand your View?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/carrier-screening-your-practice-it-time-expandyour-view/9648/
More informationBreakthrough Understanding in Pancreatic Cancer Therapy
Breakthrough Understanding in Pancreatic Cancer Therapy Recorded on: May 28, 2013 Sunil R. Hingorani, M.D., Ph.D. Associate Member Fred Hutchinson Cancer Research Center Please remember the opinions expressed
More informationSection 4 Decision-making
Decision-making : Decision-making Summary Conversations about treatments Participants were asked to describe the conversation that they had with the clinician about treatment at diagnosis. The most common
More informationThe Current Research on Stretching and Flexibility is Flawed!
Transcript from: https://www.youtube.com/watch?v=qz0ot7tbbg0 Original Article: http://stretchcoach.com/articles/proper-stretching/ The Current Research on Stretching and Flexibility is Flawed! Hi. I'm
More informationWhy Are So Many Clinicians Choosing to Practice Functional Medicine?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/integrative-and-functional-medicine-in-practice/why-are-so-manyclinicians-choosing-practice-functional-medicine/8424/
More informationLiving With Myeloma Webcast April 7, 2010 Tanya Wahl, M.D. Steve Henkel. Steve s Story
Living With Myeloma Webcast April 7, 2010 Tanya Wahl, M.D. Steve Henkel Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power.
More informationHello and welcome to Patient Power sponsored by UCSF Medical Center. I'm Andrew Schorr.
Managing Pain from Shingles Webcast August 22, 2011 George Pasvankas, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff
More informationNews from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O.
News from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O. Please remember the opinions expressed on Patient Power are not necessarily the views
More informationDr. Coakley, so virtual colonoscopy, what is it? Is it a CT exam exactly?
Virtual Colonoscopy Webcast January 26, 2009 Fergus Coakley, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationMinimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients
Minimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients Recorded on: August 1, 2012 Venu Pillarisetty, M.D. Surgical Oncologist Seattle Cancer Care Alliance Please remember the opinions
More informationMarty: I had my physical in 2006, and my physician said that I had myelofibrosis and said I had three to five years to live.
Advances in the Treatment of Myeloproliferative Disorders Webcast April 28, 2009 Srdan Verstovsek, M.D., Ph.D. Marty Prager Please remember the opinions expressed on Patient Power are not necessarily the
More informationRobotic Surgery: A Better Option for Many Head & Neck Cancers
Robotic Surgery: A Better Option for Many Head & Neck Cancers Neal Futran, MD, DMD Director of Head and Neck Surgery, Department of Otolaryngology UW Medicine Eduardo Mendez, MD Assistant Professor, Otolaryngology:
More informationAutoimmune disorders: An emerging risk factor for CV disease
Autoimmune disorders: An emerging risk factor for CV disease DR. SHARON MULVAGH: Greetings. I'm Dr Sharon Mulvagh, professor of medicine and director of Mayo Clinic Women's Heart Clinic. During today's
More informationMyeloma Myth Busters: Clinical Trials
Patient Power Knowledge. Confidence. Hope. Myeloma Myth Busters: Clinical Trials Recorded on December 8, 2014 Paul Richardson, MD Clinical Director, Jerome Lipper Center for Multiple Myeloma Dana-Farber
More informationHello and welcome to Patient Power sponsored by UW Medicine Health System. I'm Andrew Schorr
Advanced Techniques for Treating Liver Tumors Webcast James O. Park, M.D. Veena Shankaran, M.D. Raymond S.W. Yeung, M.D., FRCS(C), FACS Derek Epps November 28, 2011 Please remember the opinions expressed
More informationClinical Trials: Non-Muscle Invasive Bladder Cancer. Tuesday, May 17th, Part II
Clinical Trials: Non-Muscle Invasive Bladder Cancer Tuesday, May 17th, 2016 Part II Presented by Yair Lotan, MD is holder of the Helen J. and Robert S. Strauss Professorship in Urology and Chief of Urologic
More informationHow a CML Patient and Doctor Work Together
How a CML Patient and Doctor Work Together Recorded on: November 5, 2012 Jessica Altman, M.D. Assistant Professor, Department of Medicine, Hematology Oncology Division Feinberg School of Medicine, Northwestern
More informationHIV Housing Care Continuum Webinar 1 August 3, 2016
Page 1 HIV Housing Care Continuum August 3, 2016 Rita Flegel: Hello and welcome. I'm Rita Flegel, the Director of HUD's Office of HIV/AIDS Housing. And presenting with me today is Amy Palilonis also from
More informationBeyond The Data: Promoting Well-being in Older Adults
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/grand-rounds-nation/beyond-data-promoting-well-being-olderadults/9844/
More informationNext Level Practitioner
Next Level Practitioner - Best Advice Week 88, Day 3 - Ed Tronick, PhD - Transcript - pg. 1 Next Level Practitioner Week 88: Treatment Specific Advice Day 3: How Advice Can Change Our Outlook on Our Therapeutic
More informationThe Latest in Kidney and Liver Transplant Webcast August 14, 2008 Connie Davis, M.D. Robert Carithers, M.D. Introduction
The Latest in Kidney and Liver Transplant Webcast August 14, 2008 Connie Davis, M.D. Robert Carithers, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UW Medicine,
More informationcertain genotypes known to be associated with genetic disease or a predisposition to genetic disease
DARYL L. THULL, MS 1 Good morning. So I thought that it would be helpful to sort of go back and see what population screening for genetic disease, sort of what the definition is. And it's testing to identify
More informationeltrombopag (Promacta )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 7, Part 2 - Transcript - pg. 1 How to Foster Post-Traumatic Growth Two Ways to Ignite Accelerated Growth Part 2: How Your Choice of Language Can Transform an
More informationAplastic Anemia. is a bone marrow failure disease 9/19/2017. What you need to know about. The 4 major components of blood
What you need to know about Aplastic Anemia Stuart Goldberg MD Aplastic Anemia is a bone marrow failure disease The bone marrow is the factory that makes blood The 4 major components of blood Red Blood
More informationMark Hyman, M.D. Transcript
Mark Hyman, M.D. Transcript Mark Hyman, M.D.: I've been seeing chronically ill patients for 20 years, and there are certain patients who are resistant to getting better using functional medicine, and when
More informationPredictive analytics can spot patients not taking their medicine
Predictive analytics can spot patients not taking their medicine Using big data to find incidents of medication nonadherence, and using it to tailor patient interventions, is a key component to population
More informationNeonatal Diabetes: A Special Case of Type 1 Diabetes
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/neonatal-diabetes-a-special-case-of-type-1-
More informationAs a Lung Cancer Patient, What Information Do I Need to Make the Best Choices?
As a Lung Cancer Patient, What Information Do I Need to Make the Best Choices? Mary Ellen Hand, RN, BSN Nurse Coordinator Rush University Medical Center Emma Shtivelman, PhD Chief Scientist Cancer Commons
More informationEARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland
EARLY VERSUS LATE STEROID WITHDRAWAL Julio Pascual, Barcelona, Spain Chairs: Ryszard Grenda, Warsaw, Poland Julio Pascual, Barcelona, Spain Prof. Julio Pascal Hospital del Mar Nephrology Department Barcelona,
More informationAbhinav: So, Ephraim, tell us a little bit about your journey until this point and how you came to be an infectious disease doctor.
Announcer: Welcome to the Science is the Best Medicine podcast with your host Dr. Abhinav Sharma, exploring the pressing scientific and healthcare issues of our time. Dr. Abhinav Sharma: Superbugs we hear
More informationA Critical View of JUPITER
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/a-critical-view-of-jupiter/4124/
More informationHereditary Cancer Syndromes and the Obstetrician/Gynecologist
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/hereditary-cancer-syndromes-and-theobstetriciangynecologist/6990/
More informationUnderstanding Thyroid Cancer
Understanding Thyroid Cancer Recorded on: July 25, 2012 Christine Landry, M.D. Surgical Oncologist Banner MD Anderson Cancer Center Please remember the opinions expressed on Patient Power are not necessarily
More informationAspirin Resistance and Its Implications in Clinical Practice
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/aspirin-resistance-and-its-implications-in-clinicalpractice/3819/
More informationMaking_It_Personal Using_DNA_to_Tailor_Cancer_Treatments English mp4_
Making_It_Personal Using_DNA_to_Tailor_Cancer_Treatments English mp4_ [00:00:00.00] [00:00:20.31] PROFESSOR LIAO: Welcome to our segment on how to choose the best cancer therapy to treat individual tumors.
More informationAn Update on BioMarin Clinical Research and Studies in the PKU Community
An Update on BioMarin Clinical Research and Studies in the PKU Community Barbara Burton, MD, Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Director of PKU Clinic, Children
More informationCase Study: Biomedical Scientist - Caroline
Case Study: Biomedical Scientist - Caroline What do you do? I'm a biomedical scientist, in haematology. I work in an NHS hospital. We study the morphology of the cells - what they actually look like, such
More informationAndrew Schorr: And you're a retired businessman. Tell us about this diagnosis. What was going on for you that suddenly you were sick? What happened?
Advances in the Treatment of Stomach Cancer Webcast August 5, 2008 Linus Ho, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationHepatocellular Carcinoma: Clinical Priorities from Detection to Liver Transplantation
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-breakthroughs-from-penn-medicine/hepatocellular-carcinomaclinical-priorities-detection-liver-transplantation/7948/
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 9 - Transcript - pg. 1 How to Foster Post-Traumatic Growth Are Some Clients Predisposed for Post-Traumatic Growth? with Christine Padesky, PhD; Ron Siegel, PsyD;
More informationMS Learn Online Feature Presentation Stress and MS: What We Know Featuring Fred Foley, Ph.D.
Page 1 MS Learn Online Feature Presentation Stress and MS: What We Know Featuring Fred Foley, Ph.D. >>Kate Milliken: Hello. I'm Kate Milliken and welcome to MS Learn Online. Aside from the stress that
More informationAn Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53
An Oral Fecal Transplant for Lunch?- Frankly Speaking EP 53 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media formats
More informationMerkel Cell Carcinoma: Not Just Another Skin Cancer
Merkel Cell Carcinoma: Not Just Another Skin Cancer Merkel cell carcinoma (MCC) is a rare, aggressive, and often fatal neuroendocrine skin cancer. The incidence of MCC has been increasing in recent decades.
More informationt-test for r Copyright 2000 Tom Malloy. All rights reserved
t-test for r Copyright 2000 Tom Malloy. All rights reserved This is the text of the in-class lecture which accompanied the Authorware visual graphics on this topic. You may print this text out and use
More informationThe Parent's Perspectives on Autism Spectrum Disorder
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/autism-spectrum/the-parents-perspectives-on-autism-spectrumdisorder/6809/
More informationTRANSCRIPT. Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18
Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com.
More informationOvercoming Seasonal Affective Disorder Webcast December 19, 2011 Pamela Sheffield, M.D. Crystal Wong, M.D.
Overcoming Seasonal Affective Disorder Webcast December 19, 2011 Pamela Sheffield, M.D. Crystal Wong, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UW Medicine,
More informationRoles of Non-HDL Cholesterol in Risk Assessment and Treatment
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/lipid-luminations/roles-of-non-hdl-cholesterol-in-risk-assessment-andtreatment/7066/
More informationHow to Foster Post-Traumatic Growth
How to Foster Post-Traumatic Growth Module 3 - Transcript - pg. 1 How to Foster Post-Traumatic Growth The Critical Role of Connection in Post-Traumatic Growth with Sue Johnson, EdD; Kelly McGonigal, PhD;
More informationConversations: Let s Talk About Bladder Cancer
Understanding Biomarkers Matt Gaslky, MD, Professor of Medicine Icahn School of Medicine at Mount Sinai Piyush Agarwal, MD, Head, Bladder Cancer Section Urological Oncology Branch, National Cancer Institute
More informationColon Cancer Screening Webcast April 23, 2008 William Grady, M.D. Introduction
Colon Cancer Screening Webcast April 23, 2008 William Grady, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff
More informationAndrew Schorr: Now, snoring isn't necessarily sleep apnea, but is it an indicator most of the time?
Sleeping and Sleep Apnea: What It Means to Your Health Webcast March 22, 2011 Phyllis Zee, M.D. Rob Mehan Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern
More informationWhat s the Latest in Prostate Cancer Immunotherapy Options?
What s the Latest in Prostate Cancer Immunotherapy Options? Jeri Kim, MD Associate Professor, Department of Geritourinary Medical Oncology The University of Texas MD Anderson Cancer Center Sumit K. Subudhi,
More informationParkinson s Disease: An Update Webcast November 27, 2007 Cindy Zadikoff, M.D.
Parkinson s Disease: An Update Webcast November 27, 2007 Cindy Zadikoff, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial Hospital, its
More informationCognitive Challenges After Hormone Therapy August 26, 2009 Webcast Monique Cherrier, Ph.D. Celestia Higano, M.D. Introduction
Cognitive Challenges After Hormone Therapy August 26, 2009 Webcast Monique Cherrier, Ph.D. Celestia Higano, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of
More informationVIDEO_ Sarah Hallberg - Interview (San Diego 2017)
VIDEO_ Sarah Hallberg - Interview (San Diego 2017) Dr. Andreas Eenfeldt: If you are a doctor and you want to help your patients with type 2 diabetes to reverse their disease, how do you do it? You can
More informationAdult Asthma My Days of Living in Tension with Asthma are Over!
Published on: 9 Jul 2014 Adult Asthma My Days of Living in Tension with Asthma are Over! Introduction This is a recent picture, taken when we went on a family picnic. We climbed up this big hill and I
More informationChemotherapy Resistance: The Fault in Our Cells
Chemotherapy Resistance: The Fault in Our Cells [MUSIC PLAYING] JOHN F. KENNEDY: We choose to go to the moon. We choose to go to the moon in this decade and do the other things, not because they are easy,
More informationComparing Liquid-Based Cytology Methods in the Detection of Cervical Cancer: Perspectives from Dr. Daniel Ferrante
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-womens-health/comparing-liquid-based-cytology-methodsdetection-cervical-cancer-perspectives-dr-daniel-ferrante/7592/
More informationTargeted Therapies in Breast Cancer Webcast October 24, 2007 Julie Gralow, M.D. Hosted By Andrew Schorr
Targeted Therapies in Breast Cancer Webcast October 24, 2007 Julie Gralow, M.D. Hosted By Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationMalhotra - Interview (London 2018)
Malhotra - Interview (London 2018) Dr. Aseem Malhotra: One of the reasons we have a complete healthcare system failure is because there is a root of an epidemic of misinformed doctors and misinformed patients.
More informationTranscript of Cerebrum Podcast Fire in the Smoke: Battling Brain Tumors
Transcript of Cerebrum Podcast Fire in the Smoke: Battling Brain Tumors Guest: Michael Lim, M.D., is director of the Brain Tumor Immunotherapy Program and a professor of neurosurgery, oncology, otolaryngology,
More informationSurgical Treatment For Prostate Cancer Webcast May 6, 2010 John W. Davis, M.D., F.A.C.S. Mike Whyte. Mike s Story
Surgical Treatment For Prostate Cancer Webcast May 6, 2010 John W. Davis, M.D., F.A.C.S. Mike Whyte Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson
More informationHelping Kidney Stones Pass: Use of Alpha Antagonists Frankly Speaking EP7
Helping Kidney Stones Pass: Use of Alpha Antagonists Frankly Speaking EP7 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional
More informationPlease Understand Me, Managing ADHD within a Marriage, this is Stay Happily Married episode number 222.
Announcer: Please Understand Me, Managing ADHD within a Marriage, this is Stay Happily Married episode number 222. Welcome to Stay Happily Married, your source for weekly updates on the latest tips and
More informationProgress and Promises of Leukemia Therapy Webcast December 14, 2010 Olga Frankfurt, M.D. Christy Moore. Introduction
Progress and Promises of Leukemia Therapy Webcast December 14, 2010 Olga Frankfurt, M.D. Christy Moore Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern
More informationThe Changing Face of MDS: Advances in Treatment
Thank you very much again for listening to me. We are going to be talking now in terms of therapy of MDS or The Changing Face of MDS Advances in Treatment. My name is Guillermo Garcia-Manero. I am a Professor
More informationDiabetes Remission with Weight Loss - Frankly Speaking EP 49
Diabetes Remission with Weight Loss - Frankly Speaking EP 49 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media
More informationCLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?
FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology
More informationSurgical Options for Breast Cancer October 28, 2009 Kristine Calhoun, M.D. Suzie Hagerland. Introduction
Surgical Options for Breast Cancer October 28, 2009 Kristine Calhoun, M.D. Suzie Hagerland Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance,
More informationDetecting Coronary Artery Disease: The Role of Non-Invasive Cardiac Stress Testing Webcast September 28, 2010 Preeti Kansal, M.D.
Detecting Coronary Artery Disease: The Role of Non-Invasive Cardiac Stress Testing Webcast September 28, 2010 Preeti Kansal, M.D. Please remember the opinions expressed on Patient Power are not necessarily
More informationTop 10 things to avoid when discussing tobacco cessation
What NOT To Do Top 10 things to avoid when discussing tobacco cessation We re human. We ve all had those moments when we ve tried to convince someone to make a positive change, but the only change that
More informationAsthma and Allergies: How to Get Relief Webcast May 31, 2010 Bryna Dunaway Jennifer Creaser, A.R.N.P., F.N.P. Thomas Hei
Asthma and Allergies: How to Get Relief Webcast May 31, 2010 Bryna Dunaway Jennifer Creaser, A.R.N.P., F.N.P. Thomas Hei Please remember the opinions expressed on Patient Power are not necessarily the
More informationType 1 Diabetes: Control and Cure
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/type-1-diabetes-control-and-cure/1771/
More informationA meeting in the PGD Lab
A meeting in the PGD Lab Choose the character everyone will play. Read the scripted play out together or in front of the class. Read through the role play section of the play and discuss the answers each
More informationBBC Learning English 6 Minute English 2 October 2014 Sleeping on the job
BBC Learning English 6 Minute English 2 October 2014 Sleeping on the job NB: This is not a word for word transcript Hello I'm. Welcome to 6 Minute English. I'm joined today by. Hello..? Hello? Oh sorry,
More informationGlobal Perspectives on Organ Donation
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/focus-on-global-medicine/global-perspectives-on-organ-donation/3990/
More informationSection 4 Decision-making
Decision-making : Experience of health professional communication Conversations about s Participants were asked to describe the conversations they have had about mitochondrial disease options. The most
More informationYour 'gluten sensitivity' might not have anything to do with gluten
Saturday December 02, 2017 Your 'gluten sensitivity' might not have anything to do with gluten People with non-celiac who think they have issues digesting gluten might instead have troubles with fructan.
More informationExpert Tips to Stop Smoking Now Webcast January 17, 2011 Vicky Fang, M.D. Yunyu Cao, M.D. Introduction
Expert Tips to Stop Smoking Now Webcast January 17, 2011 Vicky Fang, M.D. Yunyu Cao, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UW Medicine, their staff,
More informationDepression. Most of the time, people manage to deal with these feelings and get past them with a little time and care.
Page 1 of 5 TeensHealth.org A safe, private place to get doctor-approved information on health, emotions, and life. Depression Lately Lindsay hasn't felt like herself. Her friends have noticed it. Kia
More informationCombining Individualized Treatment Options with Patient-Clinician Dialogue
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationFostering a "Back to Basics" Model in Type 2 Diabetes Care
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/diabetes-discourse/fostering-a-back-to-basics-model-for-type-2-
More information